PFA
FULC icon

Paradigm Financial Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Paradigm Financial Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,375
Closed -$208K – 236
2021
Q3 		$208K Buy
+7,375
New +$140K 0.05% 209

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Paradigm Financial Advisors's FULC Position: Q4 2021 in Review

Paradigm Financial Advisors sold out of Fulcrum Therapeutics (FULC) in Q4 2021, closing a stake of 7,375 shares — an estimated $208K sold.

Paradigm Financial Advisors first reported a position in FULC in Q3 2021 and held it in 1 quarter. The position peaked at $208K in Q3 2021. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2021.

  • Paradigm Financial Advisors reported no remaining Fulcrum Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Paradigm Financial Advisors sold 7,375 Fulcrum Therapeutics shares in Q4 2021, an estimated $208K.
  • Paradigm Financial Advisors first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 1 quarter.
  • Paradigm Financial Advisors's Fulcrum Therapeutics position peaked at $208K in Q3 2021.
  • 110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2021.

Based on Paradigm Financial Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.